76672-21-4

Basic information

• Product Name: 3,6-Dichloro-2-Methylquinoxaline
• Synonyms: 3,6-Dichloro-2-Methylquinoxaline
• CAS NO: 76672-21-4
• Molecular Formula: C₉H₆Cl₂N₂
• Molecular Weight: 213.06334
• Mol File: 76672-21-4.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3,6-Dichloro-2-Methylquinoxaline(CAS DataBase Reference)
• NIST Chemistry Reference: 3,6-Dichloro-2-Methylquinoxaline(76672-21-4)
• EPA Substance Registry System: 3,6-Dichloro-2-Methylquinoxaline(76672-21-4)

Safety Data

• Hazardous Substances Data: 76672-21-4(Hazardous Substances Data)

Upstream product

• 17796-60-0 7-chloro-3-methyl-1H-quinoxalin-2-one 
• 76672-27-0 6-chloro-3-methyl-2(1H)-quinoxalinone 
• 95-83-0 4-Chloro-1,2-phenylenediamine 
• 617-35-6 2-oxo-propionic acid ethyl ester 

Downstream Products

• 1392413-39-6 2-chloro-benzoic acid N'-(7-chloro-3-methyl-quinoxalin-2-yl)-hydrazide 
• 1392412-26-8 8-chloro-1-(2-chlorophenyl)-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline 

Relevant articles and documents

Design, synthesis, biological evaluation and molecular docking study on peptidomimetic analogues of XK469

XK469 is identified as a potent quinoxaline antineoplastic agent based on its significant clinical efficacy. It probably exerts its activity via DNA topoisomerase II (topo II) inhibition. To obtain more effective antineoplastic agents, a spectrum of peptidomimetic-type quinoxaline analogues of XK469 was herein designed, synthesized, and evaluated. Few compounds (e.g. 13a and 13b) exhibited obvious cytotoxicity indicated by in?vitro anti-proliferative assay. SAR investigation revealed that introducing of hydrophobic tert-butylamine or dodecylamine moiety at the 3-position of quinoxaline core is favorable for achieving a better anti-proliferative potency, while peptidomimetic derivatives only yielded moderate cytotoxicity. Compounds with improved anti-proliferative activities also demonstrated decent anti-metastatic potencies comparable with that of doxorubicin (Doxo) based on in?vivo mouse model study. The topo II-mediated kinetoplast DNA (kDNA) decatenation assay as well as molecular docking studies implicated that these compounds tend to be potent topo II inhibitors. Overall, compounds 13a and 13b, 13b in particular, standed out from various assessments and might be promising candidates for further chemical optimization.

(1,2,4)TRIAZOLO[4,3-A]QUINOXALINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASES

The invention relates to (1,2,4)triazolo[4,3-a]quinoxaline derivatives of Formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases.